Atul Pande
CIK 1643071 · last filed 2026-08-28
Atul Pande is a corporate insider who has filed 58 SEC Form 4 insider transactions across 5 companies since 2019. The most recent filing, for IMVT, was dated Aug 28, 2026. Across all open-market trades the lifetime net is −$8.4M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.7M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
KRTX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
1441 BROADWAY, 3RD FLOOR
NEW YORK, NY 10018
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| IMVT | Director | 138,231 | $26.73 | $3.69M | -$1.01M | 16 | 2026-08-28 |
| Karuna Therapeutics, Inc. (KRTX) Delisted | Director | 0 | $329.83 | $0 | -$7.50M | 26 | 2024-03-18 |
| Sio Gene Therapies Inc. (SIOX) Delisted | Director | 33,370 | $0.48 | $16.0K | $23.4K | 2 | 2021-04-19 |
| Sio Gene Therapies Inc. (AXGT) Delisted | Director | 26,740 | — | — | $62.7K | 4 | 2020-07-10 |
| Immunovant, Inc. (IMVTW) Delisted | Director | 24,700 | — | — | $0 | 2 | 2020-05-18 |
Recent Filings
58 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-08-28 | IMVT | Mixed | — | -$52.3K | EDGAR |
| 2026-07-24 | IMVT | Mixed | — | -$47.1K | EDGAR |
| 2026-06-26 | IMVT | Mixed | — | -$44.4K | EDGAR |
| 2026-06-16 | IMVT | Mixed | — | -$38.4K | EDGAR |
| 2026-06-15 | IMVT | Notice (144) | −6,000 | -$201.7K | EDGAR |
| 2026-05-20 | IMVT | Notice (144) | −6,000 | -$157.7K | EDGAR |
| 2026-05-20 | IMVT | Mixed | — | -$141.4K | EDGAR |
| 2026-04-09 | IMVT | Grant (A) | +13,880 | $0 | EDGAR |
| 2025-04-03 | IMVT | Grant (A) | +16,188 | $0 | EDGAR |
| 2024-12-04 | IMVT | Sell (S) | −7,750 | -$221.2K | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.